Anxiety symptom severity and functional recovery or relapse

Annals of Clinical Psychiatry

Volumn 21, Issue 2, 2009, Pages 81-88

  Stein, Dan J ^a,b   Bandelow, Borwin ^c   Dolberg, Ornah T ^d   Andersen, Henning F ^e   Baldwin, David S ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d H LUNDBECK A S   (Denmark)

^e NOVO NORDISK A S   (Denmark)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Generalized anxiety disorder; Recovery; Sheehan disability scale; Social anxiety disorder

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM;

ANXIETY DISORDER; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HOSPITALIZATION; HUMAN; RECURRENT DISEASE; REMISSION;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 70349569937     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602. (Pubitemid 40973434)
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627. (Pubitemid 40973437)
3. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352:2515-2523. (Pubitemid 41007867)
4. Mogotsi M, Kaminer D, Stein DJ. Quality of life in the anxiety disorders. Harv Rev Psychiatry. 2000;8:273-282. (Pubitemid 32046386)
5. Kessler RC. The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research. Acta Psychiatr Scand Suppl. 2000;(406):7-13.
6. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of the anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:427-435. (Pubitemid 29369796)
7. Stein DJ, Hollander E. The American Psychiatric Publishing Textbook of Anxiety Disorders. Washington, DC: American Psychiatric Publishing, Inc.; 2002.
8. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567-596. (Pubitemid 41578819)
9. Chisholm D, Sanderson K, Ayuso-Mateos JL, et al. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry. 2004;164:393-403. (Pubitemid 38624765)
10. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95. (Pubitemid 26373761)
11. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
12. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
13. Leucht S, Kane JM, Kissling W, et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371. (Pubitemid 41442390)
14. Leucht S, Engel RR. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology. 2006;31:406-412. (Pubitemid 43113404)
15. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31:2318-2325. (Pubitemid 44413213)
16. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67:1428-1434. (Pubitemid 44583391)
17. Baldwin DS, Huusom AK, Mæhlum E. A placebo-controlled, double-blind study of escitalopram and paroxetine in the short-term treatment of generalised anxiety disorder (GAD). Br J Psychiatry. 2006;189:264-272. (Pubitemid 44343473)
18. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9:495-505. (Pubitemid 44607202)
19. Kasper S, Stein D, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005;186:222-226. (Pubitemid 40343816)
20. Lader M, Stender K, Bürger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, doubleblind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19:241-248. (Pubitemid 39014144)
21. Montgomery SA, Nil R, Dürr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005;66:1270-1278. (Pubitemid 41546506)